Success Metrics

Clinical Success Rate
69.2%

Based on 36 completed trials

Completion Rate
69%(36/52)
Active Trials
2(3%)
Results Posted
94%(34 trials)
Terminated
16(26%)

Phase Distribution

Ph not_applicable
4
7%
Ph phase_1
9
15%
Ph phase_2
20
33%
Ph early_phase_1
1
2%
Ph phase_3
16
26%
Ph phase_4
5
8%

Phase Distribution

10

Early Stage

20

Mid Stage

21

Late Stage

Phase Distribution55 total trials
Early Phase 1First-in-human
1(1.8%)
Phase 1Safety & dosage
9(16.4%)
Phase 2Efficacy & side effects
20(36.4%)
Phase 3Large-scale testing
16(29.1%)
Phase 4Post-market surveillance
5(9.1%)
N/ANon-phased studies
4(7.3%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

67.9%

36 of 53 finished

Non-Completion Rate

32.1%

17 ended early

Currently Active

2

trials recruiting

Total Trials

61

all time

Status Distribution
Active(3)
Completed(36)
Terminated(17)
Other(5)

Detailed Status

Completed36
Terminated16
unknown5
Recruiting1
Active, not recruiting1
Not yet recruiting1

Development Timeline

Analytics

Development Status

Total Trials
61
Active
2
Success Rate
69.2%
Most Advanced
Phase 4

Trials by Phase

Early Phase 11 (1.8%)
Phase 19 (16.4%)
Phase 220 (36.4%)
Phase 316 (29.1%)
Phase 45 (9.1%)
N/A4 (7.3%)

Trials by Status

recruiting12%
terminated1626%
active_not_recruiting12%
not_yet_recruiting12%
unknown58%
withdrawn12%
completed3659%

Recent Activity

2 active trials
Showing 5 of 61
active_not_recruitingphase_2

Phase II Study Incorporating Pegylated Interferon In the Treatment For Children With High-Risk Melanoma

NCT00539591
not_yet_recruitingearly_phase_1

Efficacy and Safety of Pegylated Interferon Alpha-2β in Patients With Hepatitis B-related Hepatocellular Carcinoma After Radical Resection

NCT07553767
completedphase_3

Efficacy and Safety of MP-424, Peginterferon Alfa-2b and Ribavirin in Non-responder Genotype 2 Hepatitis C Infected Patients

NCT01468584
completedphase_3

Efficacy and Safety of MP-424/Peginterferon Alfa-2b/Ribavirin Combination in Treatment-Naïve Patients With Chronic Hepatitis C

NCT00780416
completedphase_3

Efficacy and Safety of MP-424, Peginterferon Alfa-2b and Ribavirin in Chronic Hepatitis C Who Have Not Achieved an Undetectable HCV RNA Level With Previous Interferon Based Therapy

NCT00781274
View all 61 trials

Clinical Trials (61)

Showing 20 of 61 trialsScroll for more
NCT00539591Phase 2

Phase II Study Incorporating Pegylated Interferon In the Treatment For Children With High-Risk Melanoma

Active Not Recruiting
NCT07553767Early Phase 1

Efficacy and Safety of Pegylated Interferon Alpha-2β in Patients With Hepatitis B-related Hepatocellular Carcinoma After Radical Resection

Not Yet Recruiting
NCT01468584Phase 3

Efficacy and Safety of MP-424, Peginterferon Alfa-2b and Ribavirin in Non-responder Genotype 2 Hepatitis C Infected Patients

Completed
NCT00780416Phase 3

Efficacy and Safety of MP-424/Peginterferon Alfa-2b/Ribavirin Combination in Treatment-Naïve Patients With Chronic Hepatitis C

Completed
NCT00781274Phase 3

Efficacy and Safety of MP-424, Peginterferon Alfa-2b and Ribavirin in Chronic Hepatitis C Who Have Not Achieved an Undetectable HCV RNA Level With Previous Interferon Based Therapy

Completed
NCT00780910Phase 3

Efficacy and Safety of MP-424, Peginterferon Alfa-2b, and Ribavirin in Patients With Chronic Hepatitis C Who Relapsed After Previous Interferon Based Therapy

Completed
NCT01466192Phase 3

Efficacy and Safety of MP-424, Peginterferon Alfa-2b and Ribavirin in Relapser Genotype 2 Hepatitis C Infected Patients

Completed
NCT01718301Phase 3

HIV Patients With Chronic Hepatitis C Genotype 1 Infection Who Failed Previously to Peginterferon /Ribavirin

Terminated
NCT05182463Phase 4

Peginterferon Treatment Study for Inactive Chronic Hepatitis B Patients

Recruiting
NCT01353911Phase 2

Grazoprevir (MK-5172) Administered With Peginterferon and Ribavirin in Treatment-Naïve Participants With Chronic Hepatitis C (MK-5172-003)

Completed
NCT00049530Phase 2

PEG-Interferon Alfa-2b in Treating Patients With Stage IV Melanoma

Completed
NCT00134030Phase 3

Combination Chemotherapy, PEG-Interferon Alfa-2b, and Surgery in Treating Patients With Osteosarcoma

Completed
NCT00015652Not Applicable

Interleukin-2 (IL-2), Pegylated Interferon (PEG-IFN Alfa-2b), and Ribavirin (RBV) Treatment in Patients With Hepatitis C and HIV Coinfection

Completed
NCT00006325Phase 1

Safety, Tolerability, and Anti-HIV Activity of PEG-Intron in HIV-Positive Children

Completed
NCT02112032Phase 1

Treatment of Advanced Melanoma With MK-3475 and Peginterferon

Completed
NCT03181113

Long-term Benefit in Chronic Hepatitis B Patients After Standard Peginterferon Alfa Therapy

Completed
NCT01425203Phase 3

The Effect of Boceprevir in Russian Participants Diagnosed With Chronic Hepatitis C Genotype 1 (P08160)

Completed
NCT01590225Phase 3

Efficacy and Safety of Boceprevir in Combination With Peginterferon Alfa-2b Plus Ribavirin in Pediatric Subjects With Chronic Hepatitis C Genotype 1 (P08034)

Withdrawn
NCT01964300Phase 2

Peginterferon Alfa-2b in Younger Patients With Craniopharyngioma That is Recurrent or Cannot Be Removed By Surgery

Terminated
NCT02379195Phase 1

Peginterferon and TIL Therapy for Metastatic Melanoma

Completed

Drug Details

Intervention Type
DRUG
Total Trials
61